Does the AMH Concentration Depend on the Menstrual Cycle?

University of Basel

Status: Completed

Conditions: Reproductive Sterility

Treatments: Diagnostic Test: menstrual cycle monitoring

Study type: Observational

Funder types: Other; Industry

Identifiers

NCT06330259

new AMH assay

Details and patient eligibility

About

During two none subsequent natural menstrual cycles healthy female participants will be subjected every second day to blood sampling and 3D-ultrasound examinations. Together with four other key hormones the concentration of AMH (anti-Muellerian Hormone) will be measured in the serum.

Full description

During two none subsequent natural menstrual cycles healthy female participants will be subjected every second day to blood sampling and 3D-ultrasound examinations. Together with four other key hormones the concentration of AMH will be measured in the serum. Half of the serum samples will immediately be subjected to hormone analysis whereas the other half will be stored frozen at -80 °C. After conclusion of the study the frozen samples will be subjected to re-measurment again a reference laboratory. The aim is to study the stability of the AMH Elecsys Assay under both conditions. The participants will be health women aged between 18 and 40 years. They will be grouped into a younger and an older group. They will be observed during one menstrual cycle, then they will remain unobserved during a second menstrual cycle, and then again they will be observed during a third menstrual cycle.

Enrollment: 50 patients

Sex: Female

Ages: 18 to 39 years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

• regular menstrual cycles, between 24 and 32 d.
• body mass index between 24 and 32 kg/m2
• no HIV, no Hepatitis B and C
• no smoking

Exclusion criteria

• intake of reproductive hormones, including birth control pill
• pregnancy or breastfeeding
• infertility
• polycystic ovary syndrome

Trial design

50 participants in 2 patient groups

Group A

Description:

25 younger women, aged 18 to 25 y.

Treatment:

Diagnostic Test: menstrual cycle monitoring

Group B

Description:

25 less young women, aged 26 to 39 y.

Treatment:

Diagnostic Test: menstrual cycle monitoring